Company profile
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor.
Mineralys Therapeutics has received a positive rating from employees, indicating a generally favorable work environment. However, specific details about the company's culture and management practices are not extensively discussed in the available reviews.
Employees appreciate the supportive work culture.
Many reviews highlight opportunities for professional growth.
Work-life balance is often mentioned positively.
Some employees express concerns about workload and expectations.
The company's mission and impact in the therapeutic area are frequently praised.
Sources
325 observationsLast observed
279 open roles